Cannabidiol (CBD)

Impact of Trump's Medical Marijuana Reclassification on Investors

The Trump administration reclassifies medical marijuana to Schedule III, affecting research access and investor expectations.

US Marijuana Policy: Updated Odds on Federal Rescheduling

The US government may ease marijuana restrictions, with rescheduling odds now at 42.6%. Traders adjust expectations for long-term outcomes.

Evaluating the Market Impact of Trump's Medical Marijuana Reclassification

Trump's reclassification of medical marijuana has shifted prediction markets and created new investment opportunities.

Understanding the Implications of Cannabis Rescheduling to Schedule III

The rescheduling of cannabis to Schedule III has shaken trader expectations, reflecting concerns about legal challenges and regulatory delays.

Impact of the US Justice Department's Marijuana Rescheduling on Market Dynamics

The US Justice Department's reclassification of medical marijuana has shifted market dynamics, impacting investor sentiment and trading strategies.

Market Implications of Medical Marijuana Rescheduling to Schedule III

The Acting Attorney General rescheduled medical marijuana to Schedule III, affecting market odds and trading behavior. What does this mean for investors?

Tilray Stock Volatile on Trump Cannabis Rescheduling News

Canadian Cannabis Stocks Slide Amid U.S. Regulatory Changes

Tilray Stock (TLRY): Potential Shift in Marijuana Policy

Tilray shares surged after Trump hinted at marijuana reclassification, boosting the cannabis sector but risks remain for non-U.S. companies.

Tilray Stock (TLRY): Q4 Results Weigh on Future Prospects

Tilray's Q4 2025 results show challenges, yet international sales soar 71% as company aims for turnaround.

Are Marijuana Stocks Undervalued?

Undervalued marijuana stocks are a tempting investment because, like alcohol and tobacco before them, they could potentially make investors a lot of money.

Is Aurora Cannabis Stock a Good Investment?

Will Aurora Cannabis (NASDAQ: ACB) stock ever head back above $100 a share? ACB must deliver results and regain trust to revive market value.

Is High Tide Stock a Top Pick for 2022?

Cannabis stock High Tide is aggressively expanding its global footprint and analysts are bullish. What's in store for the Canadian equity?